These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 26399160)

  • 21. A randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-Pressure Glaucoma Treatment Study.
    Krupin T; Liebmann JM; Greenfield DS; Ritch R; Gardiner S;
    Am J Ophthalmol; 2011 Apr; 151(4):671-81. PubMed ID: 21257146
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sensitization to and allergic contact dermatitis caused by Mirvaso(®) (brimonidine tartrate) for treatment of rosacea - 2 cases.
    Bangsgaard N; Fischer LA; Zachariae C
    Contact Dermatitis; 2016 Jun; 74(6):378-9. PubMed ID: 27133629
    [No Abstract]   [Full Text] [Related]  

  • 23. A review of neuropsychiatric adverse events from topical ophthalmic brimonidine.
    Cimolai N
    Hum Exp Toxicol; 2020 Oct; 39(10):1279-1290. PubMed ID: 32347114
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Allergic contact dermatitis caused by Mirvaso®, brimonidine tartrate gel 0.33%, a new topical treatment for rosaceal erythema.
    Cookson H; McFadden J; White J; White IR
    Contact Dermatitis; 2015 Dec; 73(6):366-7. PubMed ID: 26768997
    [No Abstract]   [Full Text] [Related]  

  • 25. Corneal sterile infiltration induced by topical use of ocular hypotensive agent.
    Manabe Y; Sawada A; Mochizuki K
    Eur J Ophthalmol; 2020 Sep; 30(5):NP23-NP25. PubMed ID: 31096781
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metipranolol-associated granulomatous anterior uveitis.
    Akingbehin T; Villada JR
    Br J Ophthalmol; 1991 Sep; 75(9):519-23. PubMed ID: 1680389
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of the efficacy and safety of latanoprost 0.005% compared to brimonidine 0.2% or dorzolamide 2% when added to a topical beta-adrenergic blocker in patients with primary open-angle glaucoma or ocular hypertension.
    Stewart WC; Sharpe ED; Day DG; Kolker AE; Konstas AG; Lee WH; Rieser JC; Chopra H; Holmes KT
    J Ocul Pharmacol Ther; 2000 Jun; 16(3):251-9. PubMed ID: 10872922
    [TBL] [Abstract][Full Text] [Related]  

  • 28. α2-Adrenergic modulation of the glutamate receptor and transporter function in a chronic ocular hypertension model.
    Jung KI; Kim JH; Park CK
    Eur J Pharmacol; 2015 Oct; 765():274-83. PubMed ID: 26300392
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incidence of brimonidine allergy in patients previously allergic to apraclonidine.
    Williams GC; Orengo-Nania S; Gross RL
    J Glaucoma; 2000 Jun; 9(3):235-8. PubMed ID: 10877374
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of Ultra-Small Chitosan Nanoparticles Doped with Brimonidine on the Ultra-Structure of the Trabecular Meshwork of Glaucoma Patients.
    Barwal I; Kumar R; Dada T; Yadav SC
    Microsc Microanal; 2019 Dec; 25(6):1352-1366. PubMed ID: 31018876
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of brimonidine tartrate 0.15% on scotopic pupil: controlled trial.
    Gerente VM; Biondi AC; Barbosa CP; Lottenberg CL; Paranhos A
    J Ocul Pharmacol Ther; 2007 Oct; 23(5):476-80. PubMed ID: 17900228
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of brimonidine 0.2% as adjunctive therapy for patients with glaucoma inadequately controlled with otherwise maximal medical therapy.
    thoe Schwartzenberg GW; Buys YM
    Ophthalmology; 1999 Aug; 106(8):1616-20. PubMed ID: 10442912
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metipranolol-associated nongranulomatous anterior uveitis.
    Patel NP; Patel KH; Moster MR; Spaeth GL
    Am J Ophthalmol; 1997 Jun; 123(6):843-4. PubMed ID: 9535634
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic success of latanoprost 0.005% compared to brimonidine 0.2% in patients with open-angle glaucoma or ocular hypertension.
    Stewart WC; Day DG; Stewart JA; Holmes KT; Leech JN; Rowan CT; Schwartz GF
    J Ocul Pharmacol Ther; 2000 Dec; 16(6):557-64. PubMed ID: 11132902
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The ocular hypotensive effect and safety of 0.2% brimonidine].
    Yu M; Li Y; Ge J
    Yan Ke Xue Bao; 2001 Dec; 17(4):235-8. PubMed ID: 12567513
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Topical Ganciclovir in Cytomegalovirus Anterior Uveitis.
    Antoun J; Willermain F; Makhoul D; Motulsky E; Caspers L; Relvas LJ
    J Ocul Pharmacol Ther; 2017 May; 33(4):313-318. PubMed ID: 28426277
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison between latanoprost and brimonidine efficacy and safety in Indian eyes.
    Thomas R; Parikh R; Muliyil J; George R; Paul P; Abraham LM
    Indian J Ophthalmol; 2003 Jun; 51(2):123-8. PubMed ID: 12831141
    [TBL] [Abstract][Full Text] [Related]  

  • 38. OTC brimonidine (Lumify) for ocular redness.
    Med Lett Drugs Ther; 2018 Oct; 60(1558):176. PubMed ID: 30335046
    [No Abstract]   [Full Text] [Related]  

  • 39. [Brimonidine (Mirvaso), dermal use].
    Van Genechten D
    J Pharm Belg; 2015 Jun; (2):45-6. PubMed ID: 26466509
    [No Abstract]   [Full Text] [Related]  

  • 40. Brimonidine tartarate 0.2% (Alphagan) associated granulomatous anterior uveitis.
    Goyal R; Ram AR
    Eye (Lond); 2000 Dec; 14(Pt 6):908-10. PubMed ID: 11584856
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.